The most influential Megatrends set to shape the world through 2030, identified by Euromonitor International, help businesses better anticipate market developments and lead change for their industries.
Learn moreEuromonitor addresses your unique questions and challenges across all B2B and B2C industries and geographies through custom, tailor-made research projects, designed to your specific goals.
Learn moreJun 2020
US$990Added to Cart
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE!
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE!
Like retail adult incontinence, RX/reimbursement adult incontinence benefited from an ageing population in 2019, while this product area was also boosted by growth in the number of care homes across Belgium during the review period. As the population ages, the government has sought to improve care for this group.
RX/reimbursement adult incontinence continued to benefit from growth in the number of healthcare institutions for elderly people in 2019. These institutions are fully aware of the social funds allocated for the reimbursement of these products and communicate this to their patients.
Domestic player Ontex Global remained the main player in RX/reimbursement adult incontinence in 2019, working closely with the government to supply these products. This player benefits from its strength in retail adult incontinence and AFH adult incontinence, while also being a private label supplier of these products.
Sales of RX/reimbursement adult incontinence are expected to grow by 2% in constant 2019 value terms in 2020 in light of the impact of COVID-19.
All product areas within RX/reimbursement adult incontinence have been impacted equally by shortages during the initial stages of the COVID-19 pandemic. However, these shortages are likely to be temporary, with the pandemic not expected to have a significant impact on forecast period growth as a whole.
RX/reimbursement adult incontinence is expected to see good growth in the forecast period as a whole. After the initial impact of COVID-19, demand will continue to benefit from population ageing and from the fact that the government is keen to woo elderly voters, thus continuing to promote its allowance for incontinence sufferers.
Files are delivered directly into your account within a few minutes of purchase.
Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.
Files are delivered directly into your account within a few minutes of purchase.
Discover the latest market trends and uncover sources of future market growth for the Rx/Reimbursement adult incontinence industry in Belgium with research from Euromonitor's team of in-country analysts.
Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.
If you're in the Rx/Reimbursement adult incontinence industry in Belgium, our research will save you time and money while empowering you to make informed, profitable decisions.
The Rx/Reimbursement adult incontinence in Belgium market research report includes:
Our market research reports answer questions such as:
This industry report originates from Passport, our
Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.